51656-91-8

Usage

Uses

Used in the Food and Beverage Industry:
Ethyl 2-(1,4-dioxaspiro[4.5]decan-8-ylidene)acetate is used as a flavoring agent for its ability to impart a pleasant and fruity aroma to food and beverages, enhancing the sensory experience for consumers.
Used in the Cosmetics and Personal Care Products Industry:
In this industry, ethyl 2-(1,4-dioxaspiro[4.5]decan-8-ylidene)acetate serves as a fragrance ingredient, capitalizing on its sweet, floral, and slightly woody scent to create appealing products for personal use.
Used in the Pharmaceutical Industry:
Ethyl 2-(1,4-dioxaspiro[4.5]decan-8-ylidene)acetate is utilized in the synthesis of various pharmaceuticals and organic compounds, contributing to the development of new medications and healthcare products.
Used in the Chemical Synthesis Industry:
ethyl 2-(1,4-dioxaspiro[4.5]decan-8-ylidene)acetate is employed as an intermediate in the synthesis of a range of organic compounds, showcasing its versatility and importance in chemical manufacturing processes.

InChI:InChI=1/C12H18O4/c1-2-14-11(13)9-10-3-5-12(6-4-10)15-7-8-16-12/h9H,2-8H2,1H3

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 311-46-6 ethyl 2-(dimethoxyphosphoryl)acetate 
• 38868-10-9 triethyl phosphonoacetate anion 
• 1099-45-2 ethyl (triphenylphosphoranylidene)acetate 
• 107-21-1 ethylene glycol 
• 159454-98-5 (4-oxocyclohexylidene)acetic acid ethyl ester 
• 35752-46-6 phosphonoacetic acid ethyl ester 
• 107-83-5 2-Methylpentane 
• 87151-60-8 1-oxaspiro[4.5]decan-8-one 
• 637-88-7 1,4-Cyclohexanedione 

Downstream Products

• 62141-26-8 ethyl 1,4-dioxaspiro[4.5]dec-8-ylacetate 
• 77784-04-4 O-methyl dihydrojoubertiamine 
• 142256-87-9 4-(1,4-dioxaspiro[4.5]decan-8-yl)phenol 
• 151251-82-0 8-(4-Methoxy-phenyl)-8-vinyl-1,4-dioxa-spiro[4.5]decane 
• 151251-83-1 2-[8-(4-Methoxy-phenyl)-1,4-dioxa-spiro[4.5]dec-8-yl]-ethanol 
• 151251-85-3 {2-[8-(4-Methoxy-phenyl)-1,4-dioxa-spiro[4.5]dec-8-yl]-ethyl}-dimethyl-amine 
• 151251-78-4 Acetic acid 2-hydroxy-2-[8-(4-hydroxy-phenyl)-1,4-dioxa-spiro[4.5]dec-8-yl]-ethyl ester 
• 151251-81-9 4-[8-(4-Methoxy-phenyl)-1,4-dioxa-spiro[4.5]dec-8-yl]-[1,3]dioxolane-2-thione 
• 151251-84-2 Methanesulfonic acid 2-[8-(4-methoxy-phenyl)-1,4-dioxa-spiro[4.5]dec-8-yl]-ethyl ester 
• 1421914-38-6 8-[2-(p-tolylthio)ethylidene]-1,4-dioxaspiro[4.5]decane 
• 1421914-30-8 8-(2-tosylethylidene)-1,4-dioxaspiro[4.5]decane 
• 1421914-19-3 8-(4-phenethyl-6-phenylhexa-2,3-dien-1-ylidene)-1,4-dioxaspiro[4.5]decane 
• 1613270-31-7 2-(trans-4-(2,2,11,11-tetramethyl-4,9-dioxo-3,10-dioxa-5,8-diazadodecan-6-yl)cyclohexyl)acetic acid 
• 1613270-35-1 ethyl 2-(trans-4-(2,2,11,11-tetramethyl-4,9-dioxo-3,10-dioxa-5,8-diazadodecan-6-yl)cyclohexyl)acetate 

Relevant academic research and scientific papers

Stereoselective preparation of the ABCD tetracycle of the 20-methyl analogue of aspidospermidine and related alkaloids

The natural cis[ABCD] tetracycle of the 20-methyl analogue of aspidospermidine has been synthesised, starting from the 4,4-ethylenedioxy- 1-cyclohexanone. This, was transformed into 3-methyl-3-(3'-nitropropyl)- 1,2,3,4-tetrahydrocarbazol-4-one. Two key synthetic steps permits the construction of the D ring: i) the one pot nickel boride catalyst to the imine tetracycle in excellent yield; and ii) the stereoselective reduction of this imine to the natural cis D ring junction in good yield.

Harnessing Additional Capability from in Water Reaction Conditions: Aldol versus Knoevenagel Chemoselectivity

Aldol reaction chemoselectivity, racemic or enantioselective, has not been previously demonstrated in the presence of Knoevenagel active functional groups. Here, we show that unhindered β-diketones remain unreacted while a ketone moiety undergoes a highly

Conformational-Analysis-Guided Discovery of 2,3-Disubstituted Pyridine IDO1 Inhibitors

IDO1 inhibitors have shown promise as immunotherapies for the treatment of a variety of cancers, including metastatic melanoma and renal cell carcinoma. We recently reported the identification of several novel heme-displacing IDO1 inhibitors, including the clinical molecules linrodostat (BMS-986205) and BMS-986242. Both molecules contain quinolines that, while being present in successful medicines, are known to be potentially susceptible to oxidative metabolism. Efforts to swap this quinoline with an alternative aromatic system led to the discovery of 2,3-disubstituted pyridines as suitable replacements. Further optimization, which included lowering ClogP in combination with strategic fluorine incorporation, led to the discovery of compound 29, a potent, selective IDO1 inhibitor with robust pharmacodynamic activity in a mouse xenograft model.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF HPK1

This disclosure relates to heterocyclics as inhibitors of HPK1, in particular relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound that useful for treatment of HPK1 mediated diseases and conditions such as cancer. (I)

SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR

Disclosed in the present invention are an indoleamine-2,3-dioxygenase inhibitor and a preparation method therefor. The inhibitor of the present invention has a structure as represented by general formula (I), wherein the definitions of Ar, E, Y, X, V, D, W, B, ring A and ring B are as shown in the description and claims. Also disclosed in the present invention is a preparation method for the inhibitor. The compound of general formula (I) of the present invention can be used as an indoleamine-2,3-dioxygenase inhibitor for preparing a medicament for preventing and/or treating indoleamine-2,3-dioxygenase-mediated diseases.

MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE

Provided are IDO1 inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.

MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE

Provided are IDO1 inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.

CYCLIC COMPOUNDS AS IMMUNOMODULATING AGENTS

The present disclosure describes novel IDO inhibitors and methods for preparing them. The pharmaceutical compositions comprising such IDO inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders are also described

INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3 -dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

FACTOR XIIa INHIBITORS

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.